Leo Pharma enters collaboration with Canadian biotech firm

Sequence Bio, a Canadian biotech firm, has inked a deal with Danish Leo Pharma to collaborate on identifying new dermatological targets using the former company’s technology platform.
Jörg Möller, head of global research and development at Leo Pharma | Photo: MAGNUS MØLLER
Jörg Möller, head of global research and development at Leo Pharma | Photo: MAGNUS MØLLER
by ulrich quistgaard, translated by daniel pedersen

Danish pharmaceutical firm Leo Pharma has entered a collaboration agreement with Canadian biotech firm Sequence Bio to use the latter’s proprietary discovery platform to identify dermatological targets, Sequence Bio has announced in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading